Positive Health Online
Your Country
Rationale for Mushroom Nutrition Supplementation in Neurodegenerative Conditions*
by Carolin Cornelius, Monia Cavallaro, Maria Scuto and Vittorio Calabrese(more info)
listed in neurological and neurodegenerative, originally published in issue 208 - August 2013
Rationale
The effects of edible mushrooms is an area of increasing interest associated with health benefits in a number of pathologies, mostly associated with oxidative stress and free-radical-induced cell damage(1).
Hericium Mushrooms
Neurodegenerative Processes
The brain has a large potential oxidative capacity but a limited ability to counteract oxidative stress (2-4). Within the cell, reactive oxygen species (ROS) are physiologically present at minimal concentration as by-products of aerobic metabolism as well as second messengers in many signal transduction pathways and, in normal conditions, there is a steady-state balance between pro-oxidants and antioxidants which is necessary to ensure optimal efficiency of antioxidant defences (5-8).
However, when the rate of free radical generation exceeds the capacity of antioxidant defences, oxidative stress ensues with consequential severe damage to DNA, proteins and lipids(9-11). Oxidative stress has been implicated in mechanisms leading to neuronal cell injury in various pathological states of the brain, including neurodegenerative disorders such as Alzheimer’s disease (AD)(12-16). Recently the term “nitrosative stress” has been used to indicate the cellular damage elicited by nitric oxide and occurs when intermediates are produced from nitrosate thiol, hydroxyl and amine groups as well as its congeners peroxynitrite N2O3, nitroxyl anion and nitrosonium (all can be indicated as reactive nitrogen species or RNS) (17-19).
There is growing evidence that the continuous presence of a small stimulus such as low concentrations of ROS is in fact able to induce the expression of antioxidant enzymes and other defence mechanisms. The basis for this phenomenon may be encompassed by the concept of hormesis (21), a term for generally-favourable biological responses to low exposures to toxins and other stressors and which can be characterized as a particular dose–response relationship in which a low dose of a substance is stimulatory and a high dose is inhibitory. In this context, radicals may be considered to be beneficial since they act as signals to enhance defences rather than deleterious as they are when cells are exposed to high levels of ROS.
On the other hand, oxidants, when in excess can, over long term, disrupt redox homeostasis, impose oxidative stress and subsequently lead to a dramatic loss of molecular fidelity which is the major cause for accumulation of unfolded or misfolded proteins in brain cells. Alzheimer’s (AD), Parkinson’s (PD), and Huntington’s diseases, but also amyotrophic lateral sclerosis and Friedreich ataxia belong to the so called “protein conformational diseases” and affect several millions of aged people in all the world (20).
Cells have evolved mechanisms such as the unfolded protein response, where chaperons can rescue misfolded proteins by breaking up aggregates and assisting the refolding process, while proteins thatcannot be rescued by refolding are delivered to the proteasome by other chaperones to be recycled(22). In general, an unfolded protein response conformational diseases are conditions that arise from the dysfunctional aggregation of proteins in non-native conformations. This often is associated with multiple metabolic derangements that result in the excessive production of ROS and oxidative stress (22).
The ability of a cell to deal with ROS and RNS requires the activation of pro-survival pathways as well as the production of molecules endowed with anti-oxidant and anti-apoptotic activities.
It is plausible to exploit the possibility that mushroom nutrition can activate signaling processes within brain cells leading to augmented cellular stress resistance, thereby opening novel therapeutic windows to withstand deleterious effects of oxidative damage in vulnerable neurons and consequently cell death-mediated degenerative diseases (23-45).
It has been known that enzyme therapy plays an important role in several clinical conditions such as in cancer treatment, malignant lymphoma and cardiovascular disorders(46,47). All the above evidence supports the notion that nutritional approaches with mushroom biomass can be a novel target for preventive medicine actions based on the modulation of endogenous redox state to withstand conditions of oxidative stress which is the main pathogenic factor operating in aging and neurodegenerative disorders, as well as in the promotion and progression of malignant cells.
Accordingly, a variety of proteins have been isolated and characterized from mushrooms and fungi including lectins, ribonucleases, ribosome-inactivating proteins, anti-fungal proteins, laccases and ubiquitin-like peptides Some of these proteins exhibit anti-proliferative/anti-tumour, anti-microbial and human immunodeficiency virus (HIV)-1 reverse transcriptase (RT) inhibitory activities(48). These mushroom enzymes mentioned below are thought to prevent oxidative stress as well as to inhibit cell growth in several diseases.
In view of recent findings showing that mushrooms are effective in the treatment of oxidative stress, we have determined the levels of various enzymes associated with the removal of ROS (superoxide dismutase, catalase, peroxidase, GSH-reductase, NADPH-cytochrome C reductase, laccase) as well as tyrosinase and in the following mushrooms: Polyporus umbellatus, Agaricus blazei, Pleurotus ostreatus and Hericium erinaceus.
Method
Antioxidant enzyme activities in these select mushrooms were investigated by simulating the intestinal tract of the human body with the following proteolytic enzymes:
1.Pepsin (500 IU/tablet) at pH 2 for 30 min. at 37ºC in an incubator with orbital shaking
2.Trypsin (500 IU/tablet) at pH 7.6 for 30 min. at 37ºC in an incubator with orbital shaking.
Results
It was found the following:
Table 1 Enzyme Activity in presence of Proteolytic Enzymes (U /500 mg Biomass)*
TABLE 1 |
Polyporus umbellatus |
Agaricus blazei |
Pleurotus ostreatus |
Hericium erinaceus |
Superoxide dismutase (SOD) |
11.8 10³ U |
143.5 10³ U |
13.043 10³ U |
19.430 10³ U |
Superoxide dismutase (SOD) + Pepsin |
10.4 10³ U |
115.9 10³ U |
10,671 10³ U |
17,544 10³ U |
Superoxide dismutase (SOD) + Trypsin |
11.1 10³ U |
128.7 10³ U |
11,940 10³ U |
14.961 10³ U |
NADPH Cyt. “P-450” reductase |
10,200 uM |
7,500 Um |
8,330 uM |
4,620 uM |
NADPHCyt. “P-450” reductase + Pepsin |
10,800 uM |
4,725 uM |
4,957 uM |
2,772 uM |
NADPH Cyt. “P-450” reductase + Trypsin |
11,000 uM |
7,510 uM |
3,716 uM |
5,108 uM |
GSH Reductase |
15,4 U |
510 U |
69.6 U |
21.74 U |
GSH Reductase + Pepsin |
4,3 U |
84 U |
6.9 U |
20.9 U |
GSH Reductase + Trypsin |
13.55 U |
517 U |
18.55 U |
21.80 U |
* Mycology Research Laboratories Ltd supplied the biomass samples of Agaricus blazei, Pleurotus ostreatus , Polyporus umbellatus and the Hericium erinaceus for the study. (www.mycologyresearch.com )
1. Highest levels of superoxide dismutase (SOD) (Tables 1,2) were recorded in Hericium erinaceus and Pleurotus ostreatus (19,430x103 U/500g biomass and 13,043x103 U/500g biomass, respectively), followed by Agaricus blazei (143.5x103 U/500g biomass) and Polyporus umbellatus (11.8x103 U/500g biomass). Incubation with pepsin induced a 10 to 20% decrease in enzyme activity, while trypsin decreased by 6-10%, in all species examined but Hericium erinaceus where the decrease was 20%.
2. NADPH-Cyt P450 reductase activity (Tables 1,2) was detected in all four mushroom species with Polyporus umbellatus exhibiting the highest activity (10,2 mU/500g biomass), followed by Pleurotus ostreatus (8,33 mU/500g biomass), Agaricus blazei (7,5 mU/500g biomass) and Hericium erinaceus (4,62 mU/500g biomass. In the presence of proteolytic enzymes, enzyme activity was decreased by 40% after pepsin treatment in Agaricus blazei, Pleurotus ostreatus and Hericium erinaceus. No change in the activity was found in Polyporus umbellatus. Interestingly under trypsin exposure only Pleurotus ostreatus showed a 50% reduction in the enzyme activity while in the other mushrooms no changes were measured.
3. Reduced glutathione, most commonly called glutathione or GSH, is a relatively small molecule ubiquitous in living systems. Significant levels of GSH reductase activity were measured Agaricus blazei (510 U/500g biomass), Pleurotus ostreatus (69.6 U/500g biomass) and Hericium erinaceus (21.74 U/500g biomass), with the lowest activity found in Polyporus umbellatus (15.4 U/500g biomass) (Tables 1,2). In the condition of the intestinal tract no change in the activity in Hericium erinaceus was detected under pepsin. However it was found a significant reduction of 70-80% under pepsin in Agaricus blazei, Pleurotus ostreatus and Polyporus umbellatus. With regards to trypsin effects no reduction of the enzyme activity was measured in Hericium erinaceus as well as in Agaricus blazei. Polyporus umbellatus showed a 12% reduction and Pleirozus ostreatus 34% decrease (Tables 1,2).4)
Conclusions
In conclusion, these studies suggest that important antioxidant and cytoprotective enzymes are present in all the different fungi examined, suggesting considerable potential for therapeutic strategies based on nutritional interventions with mushrooms to limit and/or prevent the adverse consequences associated with free-radical induced damage in neurodegenerative disorders.
*This article is a synopsis of two articles published in the Clinical Journal of Mycology Vol II. July 2009: http://www.mycologyresearch.com/pdf/newsletter/Clinical_Journal_of_Mycology_Vol2_July2009.pdf
- Mushroom Nutrition as a Target for Novel Therapeutic Strategies: Relevance to Nutritional Approaches and Antioxidant Redox Mondulation in Antiaging Medicine. Calabrese V.1, Cornelius C.1, Cavallaro M.1, Cambria M.1, Toscano MA2
- Comparative Enzyme Analysis of Polyporus umbellatus, Agaricus blazei , Pleurotus osteratus and Hericium erinaceus. Cornelius C.1, Cavallaro M.1, Cambria M.T.1 Toscano M.A.2 and Calabrese V.1
References
1. Angelova M, Dolashka-Angelova P, Ivanova E, Serkedjieva J, Slokoska L, Pashova S, Toshkova R, Vassilev S, Simeonov I, Hartmann HJ, Stoeva S, Weser U, Voelter W. (2001) A novel glycosylated Cu/Zn-containing superoxide dismutase: production and potential therapeutic effect. Microbiology 147, 1641-1640.
2. Halliwell B. (2008) Are polyphenols antioxidants or pro-oxidants? What do we learn from cell culture and in vivo studies? Arch Biochem Biophys. 476, 107-112.
3. Calabrese V., Scapagnini G., Colombrita C., Ravagna A., Pennisi G., Giuffrida Stella A.M., Galli F., Butterfield D.A. (2003) Redox regulation of heat shock protein expression in aging and neurodegenerative disorders associated with oxidative stress: A nutritional approach. Amino Acids 25:437-444.
4. Poon H.F., Calabrese V., Scapagnini G., Butterfield D.A. (2004) Free radicals: key to brain aging and heme oxygenase as a cellular response to oxidative stress. J. Gerontology 59:478-493.
5. Forman H.J., Fukuto J.M., Torres M. (2004) Redox signaling: thiol chemistry defines which reactive oxygen and nitrogen species can act as second messengers. Am J Physiol Cell Physiol. 287:246-256.
6. Poon H.F., Calabrese V., Scapagnini G., Butterfield D.A. (2004) Free radicals and brain aging. Clin. Geriatr. Med. 20:329-359.
7. Calabrese V., Scapagnini G., Ravagna A., Colombrita C., Spadaro F., Butterfield D.A., Giuffrida Stella A.M. (2004) Increased expression of heat shock proteins in rat brain during aging: relationship with mitochondrial function and glutathione redox state. Mech. Age Dev. 125:325-335.
8. Calabrese V., Giuffrida Stella A.M., Butterfield D.A., Scapagnini G. (2004) Redox Regulation in Neurodegeneration and Longevity: Role of the Heme Oxygenase and HSP70 Systems in Brain Stress Tolerance. Antioxid Redox Signal. 6:895-913.
9. Halliwell B. (2002) Hypothesis: proteasomal dysfunction: a primary event in neurogeneration that leads to nitrative and oxidative stress and subsequent cell death. Ann. N. Y. Acad. Sci. 962:182-194.
10. Martindale J.L., Holbrook N.J. (2002) Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol. 192:1-15.
11. Bergamini C.M., Gambetti S., Dondi A., Cervellati C. (2004) Oxygen, reactive oxygen species and tissue damage. Curr. Pharm. Des. 10:1611-1626.
12. Pappolla M.A., Chyan Y.J., Omar R.A., Hsiao K., Perry G., Smith M.A., Bozner P. (1998) Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer’s disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am J Pathol 152:871-877.
13. Smith M.A., Hirai K., Hsiao K., Pappolla M.A., Harris P.L., Siedlak S.L., Tabaton M., Perry G. (1998) Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J. Neurochem. 70:2212-2215.
14. Butterfield D.A., Drake J., Pocernich C., Castegna A. (2001) Evidence of oxidative damage in Alzheimer’s disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 7:548-554.
15. Butterfield D.A., Lauderback C.M. (2002) Lipid peroxidation and protein oxidation in Alzheimer’s disease brain: potential causes and consequences involving amyloid β-peptide-associated free radical oxidative stress. Free Rad. Biol. Med. 32:1050-1060.
16. Mattson M.P. (2004) Pathways towards and away from Alzheimer’s disease. Nature 430:631-639.
17. Drew B., Leeuwenburgh C. (2002) Aging and the role of reactive nitrogen species. Ann. NY. Acad. Sci. 959:66-81.
18. Kroncke K.D. (2003) Nitrosative stress and transcription. Biol. Chem. 384:1365-1377.
19. Ridnour L.A., Thomas D.D., Mancardi D., Espey M.G., Miranda K.M., Paolocci N., Feelisch M., Fukuto J., Wink D.A. (2004) The chemistry of nitrosative stress induced by nitric oxide and reactive nitrogen oxide species. Putting perspective on stressful biological situations. Biol. Chem. 385:1-10.
20. Mancuso C., Scapagnini G., Curro D., Giuffrida Stella A.M., De Marco C., Butterfield D.A., Calabrese V. (2007) Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front. Biosci. 12:1107-1123.
21. Calabrese E.J., Staudenmayer J.W., Stanek E.J. (2006) Drug development and hormesis: changing conceptual understanding of the dose response creates new challenges and opportunities for more effective drugs. Curr. Opin. Drug Discov. Devel. 9:117-123.
22. Zhang K., Kaufman R.J. (2006) The unfolded protein response: A stress signaling pathway critical for health and disease. Neurology 66:102-109.
23. Andersen J.K. (2004) Oxidative stress in neurodegeneration: cause or consequence? Nat. Med. 10:18-25.
24. Mancuso C., Perluigi M., Cini C., De Marco C., Giuffrida Stella A.M., Calabrese V. (2006) Heme oxygenase and cyclooxygenase in the central nervous system: a functional interplay. J. Neurosci. Res. 84:1385-1391.
25. Panahian N., Yoshiura M., Maines M.D. (1999) Overexpression of heme oxygenase-1 is neuroprotective in a model of permanent middle cerebral artery occlusion in transgenic mice. J. Neurochem. 72:1187-1203.
26. Takeda A., Perry G., Abraham N.G., Dwyer B.E., Kutty R.K., Laitinen J.T., Petersen R.B., Smith M.A. (2000) Overexpression of heme oxygenase in neuronal cells, the possible interaction with Tau. J. Biol. Chem. 275:5395-5399.
27. Premkumar D.R., Smith M.A., Richey P.L., Petersen R.B., Castellani R., Kutty R.K., Wiggert B., Perry G., Kalaria R.N. (1995) Induction of heme oxygenase-1 mRNA and protein in neocortex and cerebral vessels in Alzheimer’s disease. J. Neurochem. 65:1399-1402.
28. Schipper H.M. (2000) Heme oxygenase-1: role in brain aging and neuro-degeneration. Exp. Gerontol. 35:821-830.
29. Mancuso C., Bates T.E., Butterfield D.A., Calafato S., Cornelius C., De Lorenzo A., Dinkova Kostova A.T., Calabrese V. (2007) Natural antioxidants in Alzheimer’s disease. Expert Opin. Investig. Drugs. 16:1921-1931.
30. Butterfield D., Castegna A., Pocernich C., Drake J., Scapagnini G., Calabrese V. (2002) Nutritional approaches to combat oxidative stress in Alzheimer’s disease. J. Nutr. Biochem. 13:444-461.
31. Scapagnini G., Colombrita C., Amadio M., D’Agata V., Arcelli E., Sapienza M., Quattrone A., Calabrese V. (2006) Curcumin activates defensive genes and protects neurons against oxidative stress. Antioxid. Redox. Signal. 8:395-403.
32. Ganguli M., Chandra V., Kamboh M.I., Johnston J.M., Dodge H.H., Thelma B.K., Juyal R.C., Pandav R., Belle S.H., DeKosky S.T. (2000) Apolipoprotein E polymorphism and Alzheimer disease: The Indo-US Cross-National Dementia Study. Arch. Neurol. 57:824-830.
33. Lim G.P., Chu T., Yang F., Beech W., Frautschy S.A., Cole G.M. (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 21:8370-8377.
34. Wu L., Wang R. (2005) Carbon monoxide: endogenous production, physiological functions, and pharmacological applications. Pharmacol. Rev. 57:585-630.
35. Kostoglou-Athanassiou I., Forsling M.L., Navarra P., Grossman A.B. (1996) Oxytocin release is inhibited by the generation of carbon monoxide from the rat hypothalamus--further evidence for carbon monoxide as a neuromodulator. Brain Res Mol. Brain Res. 42:301-306.
36. Mancuso C., Kostoglou-Athanassiou I., Forsling M.L., Grossman A.B., Preziosi P., Navarra P., Minotti G. (1997) Activation of heme oxygenase and consequent carbon monoxide formation inhibits the release of arginine vasopressin from rat hypothalamic explants. Molecular linkage between heme catabolism and neuroendocrine function. Brain Res. Mol. Brain Res. 50:267-276.
37. Mancuso C., Ragazzoni E., Tringali G., Liberale I., Preziosi P., Grossman A., Navarra P. (1999) Inhibition of heme oxygenase in the central nervous system potentiates endotoxin-induced vasopressin release in the rat. J. Neuroimmunol. 99:189-194.
38. Parkes D., Kasckow J., Vale W. (1994) Carbon monoxide modulates secretion of corticotropin-releasing factor from rat hypothalamic cell cultures. Brain Res. 646:315-318.
39. Yoo B.C., Seidl R., Cairns N., Lubec G. (1999) Heat-shock protein 70 levels in brain of patients with Down syndrome and Alzheimer’s disease. J. Neural. Transm. Suppl. 57:315-322
40. Morrison-Bogorad M., Zimmerman A.L., Pardue S. (1995) Heat-shock 70 messenger RNA levels in human brain: correlation with agonal fever. J. Neurochem. 64:235-246.
41. Kakimura J., Kitamura Y., Takata K., Umeki M., Suzuki S., Shibagaki K., Taniguchi T., Nomura Y., Gebicke-Haerter P.J., Smith M.A., Perry G., Shimohama S. (2002) Microglial activation and amyloid-beta clearance induced by exogenous heat-shock proteins. FASEB J. 16:601-603.
42. Calabrese V., Testa G., Ravagna A., Bates T.E., Stella A.M. (2000) HSP70 induction in the brain following ethanol administration in the rat: regulation by glutathione redox state. Biochem Biophys. Res. Commun. 269:397-400.
43. Calabrese V., Bates T.E., Giuffrida Stella A.M. (2000) NO synthase and NO-dependent signal pathways in brain aging and neurodegenerative disorders: the role of oxidant/antioxidant balance. Neurochem. Res. 65:1315-1341.
44. Yamawaki H., Haendeler J., Berk B.C. (2003) Thioredoxin: a key regulator of cardiovascular homeostasis. Circ. Res. 93:1029-1033.
45. Cho C.G., Kim H.J., Chung S.W., Jung K.J., Shim K.H., Yu B.P., Yodoi J., Chung H.Y. (2003) Modulation of glutathione and thioredoxin systems by calorie restriction during the aging process. Exp. Gerontol. 38:539-548.
46. Mockett, R. J., Sohal, R. S., Orr, W. C. (1999) Overexpression of glutathione reductase extends survival in transgenic Drosophila melanogaster under hyperoxia but not normoxia. FASEB J. 13, 1733–1742
47. Harhaji Lj., Mijatovi, S, Maksimovi,-Ivani, D, Stojanovi, I, Momcilovi, M, Maksimovi, V, Tufegdzi, S, Marjanovi, Z, Mostarica-Stojkovi, M, Vucini, Z, Stosi,-Grujici, S. Anti-tumor effect of Coriolus versicolor methanol extract against mouse B16 melanoma cells: in vitro and in vivo study, (2008) Food Chem Toxicol 46, 1825-1833.
48. Wang HX, Ng TB. (2006) A laccase from the medicinal mushroom Ganoderma lucidum. Appl Microbiol Biotechnol. 72, 508-513.
Comments:
-
No Article Comments available